Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (311-320 of 520) with videos related to

Pageof 52
Sort By:
European Heart Journal|June 7, 2006
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeJohn J V McMurray, Fredrik L Andersson, Simon Stewart, et al.
Journal of the American College of Cardiology|November 13, 2007
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM ProgramAkshay S Desai, Karl Swedberg, John J V McMurray, et al.
Circulation|November 21, 2007
Influence of albuminuria on cardiovascular risk in patients with stable coronary artery diseaseScott D Solomon, Julie Lin, Caren G Solomon, et al.
Circulation. Heart Failure|January 26, 2018
Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic AssociationsPeter van der Meer, Niels Grote Beverborg, Marc A Pfeffer, et al.
European Heart Journal. Acute Cardiovascular Care|August 1, 2025
Long-term outcomes of recurrent myocardial infarction: a nationwide Danish studyDaniel Mølager Christensen, Deewa Zahir, Caroline Hartwell Garred, et al.
The New England Journal of Medicine|November 27, 2009
A sensitive cardiac troponin T assay in stable coronary artery diseaseTorbjørn Omland, James A de Lemos, Marc S Sabatine, et al.
American Heart Journal|August 10, 2005
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)Shelby D Reed, Jasmina I Radeva, Kevin P Weinfurt, et al.
Circulation|June 15, 2007
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programEileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
American Heart Journal|October 11, 2011
Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or bothAmil M Shah, Chung-Lieh Hung, Sung Hee Shin, et al.
JACC. Heart Failure|April 11, 2021
Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialMuthiah Vaduganathan, Jonathan W Cunningham, Brian L Claggett, et al.
Pageof 52

Showing results (311-320 of 520) with videos related to

Sort By:
Pageof 52
European Heart Journal|June 7, 2006
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeJohn J V McMurray, Fredrik L Andersson, Simon Stewart, et al.
Journal of the American College of Cardiology|November 13, 2007
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM ProgramAkshay S Desai, Karl Swedberg, John J V McMurray, et al.
Circulation|November 21, 2007
Influence of albuminuria on cardiovascular risk in patients with stable coronary artery diseaseScott D Solomon, Julie Lin, Caren G Solomon, et al.
Circulation. Heart Failure|January 26, 2018
Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic AssociationsPeter van der Meer, Niels Grote Beverborg, Marc A Pfeffer, et al.
European Heart Journal. Acute Cardiovascular Care|August 1, 2025
Long-term outcomes of recurrent myocardial infarction: a nationwide Danish studyDaniel Mølager Christensen, Deewa Zahir, Caroline Hartwell Garred, et al.
The New England Journal of Medicine|November 27, 2009
A sensitive cardiac troponin T assay in stable coronary artery diseaseTorbjørn Omland, James A de Lemos, Marc S Sabatine, et al.
American Heart Journal|August 10, 2005
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)Shelby D Reed, Jasmina I Radeva, Kevin P Weinfurt, et al.
Circulation|June 15, 2007
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programEileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
American Heart Journal|October 11, 2011
Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or bothAmil M Shah, Chung-Lieh Hung, Sung Hee Shin, et al.
JACC. Heart Failure|April 11, 2021
Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialMuthiah Vaduganathan, Jonathan W Cunningham, Brian L Claggett, et al.
Pageof 52